Patients @ years of age with stage IV nonsquamous NSCLC ( American Joint Committee on Cancer v@ @ ) , and Eastern Cooperative Oncology Group performance status @/@ were randomized ( @:@ ) to four cycles of induction Pem + Cb ( pemetrexed , @ mg/m , carboplatin , area under the curve = @ ) followed by Pem maintenance or Pac + Cb + Bev ( paclitaxel , @ mg/m , carboplatin , area under the curve = @ , and bevacizumab , @ mg/kg ) followed by Bev maintenance in the absence of progressive disease or discontinuation .